Taking medication consistently is one of the most effective ways to maintain remission in inflammatory bowel disease (IBD), yet many people find it difficult to stay on track. Missed doses, interruptions and early discontinuation are common, even when treatment is working. Understanding why adherence matters and identifying practical strategies to support it can make a meaningful difference to long-term disease control and quality of life.
What is medication adherence?
Medication adherence refers to how closely a person follows their prescribed treatment plan, including taking the correct dose at the correct time and continuing for the recommended duration. In IBD, this applies to oral tablets, injections, infusions and rectal preparations. Adherence is not simply about collecting prescriptions, but whether medication is used as intended over weeks, months and years.
Non-adherence can be intentional, where a person decides to stop or reduce their dose, or unintentional, where doses are missed due to forgetfulness, complexity or logistical challenges. Both types are common in Crohn’s disease and ulcerative colitis.
Why adherence matters in IBD
Inflammatory bowel disease is characterised by periods of active inflammation and remission. The goal of long-term treatment is to maintain remission, prevent flares, reduce structural damage to the bowel and lower the risk of complications such as strictures, fistulas and surgery.
When medication is taken inconsistently, inflammation can return even without symptoms. This subclinical inflammation, detectable through blood tests, stool markers or endoscopy, gradually causes harm. Over time, poorly controlled disease increases the likelihood of hospitalisation, escalation to stronger treatments and irreversible bowel damage.
Adherence also affects how well certain therapies work. Biologics, for example, block specific inflammatory pathways. Missed doses or irregular intervals can reduce drug levels in the blood, weakening the response and increasing the risk of developing antibodies against the drug. Once antibodies form, the medication may lose effectiveness, limiting future treatment options.
Common barriers to adherence
Side effects and tolerability
Some medications cause side effects such as nausea, headache, fatigue or injection site reactions. When side effects are troublesome, people may reduce the dose or stop without discussing it with their clinical team. Fear of side effects, even if they have not yet occurred, can also reduce adherence.
Complexity of regimen
IBD treatment plans can involve multiple medications, varying doses and different schedules. Some therapies require specific timing in relation to meals or other drugs. Rectal preparations may feel difficult or uncomfortable to use. The more complex the regimen, the higher the likelihood of unintentional non-adherence.
Feeling well
One of the most common reasons for stopping medication is feeling better. When symptoms resolve, it can seem unnecessary to continue treatment. However, the absence of symptoms does not always mean the absence of inflammation. Stopping medication during remission significantly raises the risk of relapse.
Concerns about long-term use
Worries about dependency, immune suppression or unknown long-term effects can lead people to stop medication independently. Misinformation from unreliable sources or conflicting advice from friends and family can reinforce these concerns.
Practical and financial factors
Prescription costs, frequent hospital visits for infusions, difficulties accessing repeat prescriptions or challenges fitting medication into daily routines all contribute to lapses in adherence. These factors disproportionately affect people with demanding work schedules, caring responsibilities or limited support.
Strategies to improve adherence
Understand your treatment plan
Ask your gastroenterologist or IBD nurse to explain why each medication has been prescribed, what it does, how long you will need to take it and what might happen if you stop. Understanding the purpose of your treatment and the risks of discontinuation helps reinforce commitment, particularly during remission.
Communicate openly about side effects
If side effects occur, speak to your clinical team before adjusting your dose. Many side effects can be managed with dose adjustments, timing changes or supportive medications. Stopping treatment without medical input may lead to a flare that is harder to control.
Simplify your routine
Where possible, align medication times with daily habits such as meals, brushing your teeth or bedtime. Use a pill organiser to pre-sort doses for the week. Set reminders on your phone or use a medication adherence app. If you are prescribed multiple therapies, ask whether any can be consolidated or streamlined.
Address practical barriers
If cost is a concern, ask your pharmacy or IBD team about patient assistance schemes, generic alternatives or options to reduce the financial burden. If attending infusions is difficult, discuss the possibility of home administration or a switch to a subcutaneous therapy. If you struggle with injections, request training or support from an IBD nurse.
Monitor your own disease
Keeping a simple record of symptoms, bowel frequency and how you feel over time can help you notice patterns and understand the impact of your treatment. Some people find it motivating to see tangible evidence that their medication is working, even when they feel well.
Involve your support network
Tell a trusted family member, friend or partner about your treatment plan and ask them to support you in staying consistent. This might mean reminding you to take your medication, helping you keep track of appointments or simply understanding why adherence is important.
When to seek advice
If you are considering stopping or reducing your medication, always discuss it with your gastroenterology team first. They can assess your current disease activity using objective markers, discuss the risks of discontinuation and help you make an informed decision. If you have already missed doses or stopped treatment, contact your team as soon as possible. Restarting quickly may prevent a full relapse.
Practical takeaways
- Take your medication exactly as prescribed, even when you feel well.
- Speak to your clinical team before making any changes to your treatment plan.
- Use reminders, routines and organisers to reduce unintentional missed doses.
- Discuss side effects or concerns openly rather than stopping medication independently.
- Ask about practical support if cost, access or administration is difficult.
- Keep track of your symptoms and wellbeing to help you see the benefit of consistent treatment.
Conclusion
Medication adherence is one of the most important factors in achieving long-term remission and preventing complications in IBD. While staying on track with treatment can be challenging, understanding why it matters and identifying strategies that work for your circumstances can support better outcomes. If barriers arise, discuss them with your gastroenterology team. Open communication and tailored support make adherence more achievable and sustainable.
References
- Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf. 2011;10(6):863-870. doi:10.1517/14740338.2011.583915
- Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47. doi:10.1111/j.1524-4733.2007.00213.x
- Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105(3):525-539. doi:10.1038/ajg.2009.685
- Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983-1028. doi:10.1007/s12325-015-0256-7
- Kirchgesner J, Desai RJ, Schneeweiss MC, et al. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn’s disease. Gut. 2022;71(7):1781-1789. doi:10.1136/gutjnl-2022-327002
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.